Reaction Details |
| Report a problem with these data |
Target | Tyrosine-protein kinase Lck |
---|
Ligand | BDBM50375682 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | ChEMBL_473903 (CHEMBL950179) |
---|
IC50 | 1±n/a nM |
---|
Citation | La, DS; Belzile, J; Bready, JV; Coxon, A; DeMelfi, T; Doerr, N; Estrada, J; Flynn, JC; Flynn, SR; Graceffa, RF; Harriman, SP; Larrow, JF; Long, AM; Martin, MW; Morrison, MJ; Patel, VF; Roveto, PM; Wang, L; Weiss, MM; Whittington, DA; Teffera, Y; Zhao, Z; Polverino, AJ; Harmange, JC Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis. J Med Chem51:1695-705 (2008) [PubMed] Article |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
Tyrosine-protein kinase Lck |
---|
Name: | Tyrosine-protein kinase Lck |
Synonyms: | 2.7.10.2 | LCK | LCK_HUMAN | LSK | Leukocyte C-terminal Src kinase | Lymphocyte cell-specific protein-tyrosine kinase | Lymphocyte-specific protein tyrosine kinase | P56-LCK | Protein YT16 | Proto-oncogene Lck | Proto-oncogene tyrosine-protein kinase LCK | Src/Lck kinase | T cell-specific protein-tyrosine kinase |
Type: | n/a |
Mol. Mass.: | 57987.83 |
Organism: | Homo sapiens (Human) |
Description: | P06239 |
Residue: | 509 |
Sequence: | MGCGCSSHPEDDWMENIDVCENCHYPIVPLDGKGTLLIRNGSEVRDPLVTYEGSNPPASP
LQDNLVIALHSYEPSHDGDLGFEKGEQLRILEQSGEWWKAQSLTTGQEGFIPFNFVAKAN
SLEPEPWFFKNLSRKDAERQLLAPGNTHGSFLIRESESTAGSFSLSVRDFDQNQGEVVKH
YKIRNLDNGGFYISPRITFPGLHELVRHYTNASDGLCTRLSRPCQTQKPQKPWWEDEWEV
PRETLKLVERLGAGQFGEVWMGYYNGHTKVAVKSLKQGSMSPDAFLAEANLMKQLQHQRL
VRLYAVVTQEPIYIITEYMENGSLVDFLKTPSGIKLTINKLLDMAAQIAEGMAFIEERNY
IHRDLRAANILVSDTLSCKIADFGLARLIEDNEYTAREGAKFPIKWTAPEAINYGTFTIK
SDVWSFGILLTEIVTHGRIPYPGMTNPEVIQNLERGYRMVRPDNCPEELYQLMRLCWKER
PEDRPTFDYLRSVLEDFFTATEGQYQPQP
|
|
|
BDBM50375682 |
---|
n/a |
---|
Name | BDBM50375682 |
Synonyms: | CHEMBL270057 |
Type | Small organic molecule |
Emp. Form. | C27H25N3O5 |
Mol. Mass. | 471.5045 |
SMILES | COc1cc2nccc(Oc3ccc4N(CCOc4c3)C(=O)Nc3cccc(C)c3)c2cc1OC |
Structure |
|